Marker Therapeutics (MRKR) Earnings Analysis

Marker Therapeutics (MRKR) next reports earnings on 2026-08-13, consensus EPS -0.25 USD. Last quarter (2026-05-15) it beat with EPS -0.16 USD vs -0.18 USD est (+11.1%). It has beaten estimates in 7/8 recent quarters (88%). Trailing P/E -1.85.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MRKR next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.25 USD
Revenue estimate0.00B

MRKR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-0.16 USD-0.18 USD+11.1%Beat
2026-03-18-0.04 USD-0.21 USD+81%Beat
2025-11-13-0.12 USD-0.36 USD+66.7%Beat
2025-08-14-0.29 USD-0.30385 USD+4.6%Beat
2025-05-21-0.27 USD-0.66 USD+59.1%Beat
2025-03-31-0.42 USD-0.22 USD-90.9%Miss
2024-11-14-0.26 USD-0.39 USD+33.3%Beat
2024-08-14-0.29 USD-0.43 USD+32.6%Beat

Beat rate: 7/8 (88%) over reported quarters with consensus data.

MRKR valuation and analyst view

Trailing P/E-1.85
Trailing EPS-0.56417 USD
Price / book1.74
Dividend yield0.00%
Market cap0.01B
Analyst consensusBuy (3 buy / 2 hold / 0 sell)

Related research pages

Frequently asked questions

When is Marker Therapeutics (MRKR)'s next earnings date?

Marker Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.25 USD and revenue estimate of 0.00B.

Did MRKR beat earnings last quarter?

In its 2026-05-15 report, MRKR posted EPS of -0.16 USD versus a -0.18 USD estimate — a beat of 11.1%.

What is MRKR's earnings track record?

Over the last 8 reported quarters with consensus data, MRKR beat estimates 7 times (88%).

What is MRKR's current P/E ratio and EPS?

MRKR trades at a trailing P/E of -1.85 on trailing EPS of -0.5641656512937113 USD.

What do analysts rate MRKR?

Analyst consensus is "Buy" across 5 ratings (1 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell).